Velpatasvir

Velpatasvir is a direct-acting antiviral (DAA) medication used in combination with sofosbuvir for the treatment of adults with chronic hepatitis C virus (HCV) infection. It is a hepatitis C virus (HCV) NS5A inhibitor, which works by blocking an enzyme that is essential for the virus to replicate. Velpatasvir is only available as part of a fixed-dose combination with sofosbuvir and is not available as a standalone medication. The combination of velpatasvir and sofosbuvir is used to treat all six genotypes of HCV infection. It is taken orally once daily for 12 weeks. Common side effects include headache, fatigue, and nausea.

Velpatasvir is an antiviral medication used in combination with other drugs to treat chronic hepatitis C virus (HCV) infection. Here's a breakdown of its key points:

  • Function: Inhibits viral replication: Velpatasvir belongs to a class of drugs called NS5A inhibitors. It specifically targets a protein (NS5A) on the hepatitis C virus that's essential for viral replication. By inhibiting this protein, velpatasvir helps prevent the virus from multiplying in the body.
  • Use: Combination therapy for HCV: Velpatasvir is not used alone for treatment. It's prescribed in combination with other antiviral medications, depending on the specific type of HCV infection and the patient's treatment history.
  • Mechanism of action: As mentioned earlier, velpatasvir works by blocking the NS5A protein on the HCV virus. This disrupts the virus's ability to replicate and spread within the liver cells.
  • Administration: Oral medication: Velpatasvir is typically taken as a tablet once daily, with or without food.

Here are some additional points to consider:

  • Treatment duration: The duration of HCV treatment with velpatasvir-based regimens can vary depending on the specific HCV genotype, liver function, and treatment history. It usually ranges from 8 to 12 weeks [1].
  • Side effects: Velpatasvir is generally well-tolerated, but some side effects can occur. Common ones reported in clinical trials include fatigue, headache, and nausea [1].
  • Drug interactions: Velpatasvir can interact with other medications. It's crucial to inform your doctor about all the medications you're taking before starting velpatasvir treatment.
Anatomical Therapeutic Chemical Classification
J - Antiinfectives for systemic use
J05 Antivirals for systemic use
J05A - Direct acting antiviral drugs
J05AP Antivirals for treatment of HCV infections
Anatomical Therapeutic Chemical Classification
J - Antiinfectives for systemic use
J05 Antivirals for systemic use
J05A - Direct acting antiviral drugs
J05AP Antivirals for treatment of HCV infections
External Links